What is a peptide, really?

A peptide is a short chain of amino acids linked by peptide bonds — the same chemical bond that holds proteins together. The line between a peptide and a protein is fuzzy, but the working convention in biochemistry is that anything under roughly 50 amino acids is called a peptide, and longer chains are called proteins. Insulin, at 51 residues across two chains, sits right at that border and is often used as the textbook example.

Every amino acid has the same backbone — an amine group, a carboxylic acid group, and a side chain that gives it its identity. When two amino acids join, the carboxyl of one reacts with the amine of the next, releasing a water molecule and forming the peptide bond. Repeat that twenty or thirty times and you have a peptide with a defined sequence, a defined three-dimensional shape, and a defined biological job.

Most prescription drugs are small molecules — synthetic compounds usually under 500 daltons that diffuse easily across cell membranes and are typically taken orally. Peptides are an order of magnitude larger, more polar, and built from the same building blocks your body already uses. That changes almost everything about how they behave.

Because peptides look like the body's own signaling molecules, they tend to act on specific receptors with high selectivity. A small molecule may hit several unrelated targets and cause off-target side effects; a well-designed peptide is more likely to engage one receptor family and stop there. The trade-off is delivery: peptides are digested in the gut like any other protein, so most are administered by injection, nasal spray, or specialized oral formulations.

Very short peptides (two to ten residues) are often signaling fragments — think of carnosine, glutathione, or oxytocin. They diffuse quickly, clear quickly, and frequently act as messengers between cells.

Mid-length peptides (ten to forty residues) make up most therapeutic peptides, including GLP-1 analogs, calcitonin, and many growth-hormone-releasing peptides. They are large enough to fold into a stable shape and engage a receptor with precision, but small enough to be manufactured by solid-phase synthesis rather than recombinant cell culture.

Once you cross roughly 50 residues, you are in protein territory, and manufacturing usually shifts to engineered yeast or mammalian cells. Insulin, growth hormone, and erythropoietin are produced this way.

The dominant manufacturing method is solid-phase peptide synthesis, developed by Bruce Merrifield in 1963 (work that won him the Nobel Prize in Chemistry in 1984). Amino acids are added one at a time to a growing chain anchored to a resin bead, with protecting groups preventing unwanted side reactions. After the sequence is complete, the peptide is cleaved from the resin and purified — usually by reverse-phase HPLC.

Quality is then verified by mass spectrometry (to confirm the correct molecular weight) and by analytical HPLC (to confirm purity, typically reported as a percentage of the main peak). A reputable Certificate of Analysis will show both.

Understanding that peptides are short protein fragments — not exotic synthetic chemicals — reframes a lot of the conversation around them. They are studied in the same labs, by the same chemists, using the same analytical tools as any other class of biologic. The science is mature; what is new is how quickly the field is producing well-characterized sequences for research use.